ATE292677T1 - Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe - Google Patents

Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe

Info

Publication number
ATE292677T1
ATE292677T1 AT00964563T AT00964563T ATE292677T1 AT E292677 T1 ATE292677 T1 AT E292677T1 AT 00964563 T AT00964563 T AT 00964563T AT 00964563 T AT00964563 T AT 00964563T AT E292677 T1 ATE292677 T1 AT E292677T1
Authority
AT
Austria
Prior art keywords
methods
compositions
dna
agents
damageing
Prior art date
Application number
AT00964563T
Other languages
English (en)
Inventor
Masashi Suganuma
Takumi Kawabe
Original Assignee
Canbas Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP26939899A external-priority patent/JP2001086991A/ja
Priority claimed from JP34032299A external-priority patent/JP2001157585A/ja
Application filed by Canbas Co Ltd filed Critical Canbas Co Ltd
Application granted granted Critical
Publication of ATE292677T1 publication Critical patent/ATE292677T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
AT00964563T 1999-09-22 2000-09-21 Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe ATE292677T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP26939899A JP2001086991A (ja) 1999-09-22 1999-09-22 オリゴペプチド
JP34032299A JP2001157585A (ja) 1999-11-30 1999-11-30 抗癌療法の増強剤とそのスクリーニング方法
PCT/IB2000/001438 WO2001021771A2 (en) 1999-09-22 2000-09-21 Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents

Publications (1)

Publication Number Publication Date
ATE292677T1 true ATE292677T1 (de) 2005-04-15

Family

ID=26548750

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00964563T ATE292677T1 (de) 1999-09-22 2000-09-21 Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe

Country Status (11)

Country Link
US (2) US6881575B1 (de)
EP (1) EP1218494B1 (de)
JP (1) JP4610828B2 (de)
AT (1) ATE292677T1 (de)
AU (1) AU7548500A (de)
CA (1) CA2385257A1 (de)
DE (1) DE60019318T2 (de)
DK (1) DK1218494T3 (de)
ES (1) ES2239037T3 (de)
PT (1) PT1218494E (de)
WO (1) WO2001021771A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003052483A1 (fr) * 2001-12-17 2003-06-26 Olympus Corporation Systeme de microscope
IL162836A0 (en) * 2002-01-17 2005-11-20 Canbas Co Ltd Peptides and peptidommetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments
MXPA04006894A (es) 2002-01-18 2004-10-15 Cargill Inc Alanina 2,3 - aminomutasa.
IL165323A0 (en) 2002-06-06 2006-01-15 Canbas Co Ltd Compounds that abrogate dna-damage-induced cell c ycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments
SI1585749T1 (sl) 2003-01-09 2008-10-31 Pfizer Derivati diazepinoindola kot inhibitorji kinaze
US7125842B2 (en) * 2003-04-07 2006-10-24 Canbas Co. Ltd. Anti-fungal compounds and methods of use
US7132440B2 (en) 2003-04-17 2006-11-07 Janssen Pharmaceutica, N.V. Substituted benzimidazoles and imidazo-[4,5]-pyridines
US20070172425A1 (en) * 2003-05-29 2007-07-26 Dongfang Liu Testing cell cycle regulation effect of a compound using a hollow fibre cell implant
WO2004112820A2 (en) * 2003-06-25 2004-12-29 Canbas Co., Ltd. Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activity
JP2007501608A (ja) * 2003-08-08 2007-02-01 株式会社 キャンバス 抗癌治療の効力を推定するための感受性試験
WO2005021554A1 (en) 2003-08-29 2005-03-10 Pfizer Inc. Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
WO2005027907A1 (en) * 2003-09-17 2005-03-31 Icos Corporation Use of chk1 inhibitors to control cell proliferation
CA2572218C (en) 2004-06-30 2013-06-11 Janssen Pharmaceutica, N.V. Aryl-substituted benzimidazole and imidazopyridine ethers as anti-cancer agents
AU2008294410B2 (en) 2007-04-11 2012-09-06 Canbas Co., Ltd. Compounds with anti-cancer activity
MX2009012054A (es) 2007-05-08 2009-11-19 Schering Corp Metodos de tratamiento que usan formulaciones intravenosas que comprenden temozolomida.
UY31826A (es) * 2008-05-14 2010-01-05 Takeda Pharmaceutical Compuesto peptídico y su uso
WO2010016005A1 (en) 2008-08-06 2010-02-11 Pfizer Inc. 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors
WO2017143397A1 (en) * 2016-02-23 2017-08-31 Monash University INHIBITORS OF β-ARRESTIN-NEUROKININ 1 RECEPTOR INTERACTIONS FOR THE TREATMENT OF PAIN
CN114470178A (zh) * 2019-12-05 2022-05-13 王连生 一种促进心肌再生的重组人chk1蛋白激酶水凝胶及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443962A (en) * 1993-06-04 1995-08-22 Mitotix, Inc. Methods of identifying inhibitors of cdc25 phosphatase
WO1998030680A2 (en) * 1997-01-13 1998-07-16 Pharmacia & Upjohn Company Special catalytic domains of cdc25c phosphatase

Also Published As

Publication number Publication date
US6881575B1 (en) 2005-04-19
ES2239037T3 (es) 2005-09-16
DE60019318D1 (de) 2005-05-12
EP1218494A2 (de) 2002-07-03
JP2003518368A (ja) 2003-06-10
AU7548500A (en) 2001-04-24
DK1218494T3 (da) 2005-08-08
PT1218494E (pt) 2005-08-31
WO2001021771A2 (en) 2001-03-29
US20050059116A1 (en) 2005-03-17
US7851592B2 (en) 2010-12-14
WO2001021771A3 (en) 2002-02-14
EP1218494B1 (de) 2005-04-06
JP4610828B2 (ja) 2011-01-12
CA2385257A1 (en) 2001-03-29
DE60019318T2 (de) 2006-03-09

Similar Documents

Publication Publication Date Title
ATE292677T1 (de) Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
WO2005030121A3 (en) Compounds, compositions and methods
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
DE60029799D1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
BRPI0409367A (pt) derivados de piperidina inibidores de renina
DE60223262D1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
NO20033858L (no) Aryl- og heteroarylurea-CHK1-inhibitorer for anvendelse som radiosensitiviseringsmidler og chamosensitiviseringsmidler
TW200607513A (en) Certain chemical entities, compositions, and methods
TW200634012A (en) 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents
AU2005253776A8 (en) Screening methods using c-Abl, Fyn and Syk in combination with tau protein
NO20061194L (no) Mitotiske kinesininbibitorer
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
ATE544748T1 (de) Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
ATE512146T1 (de) Phenylharnstoffderivate als hemmstoffe von tyrosinkinasen zur behandlung von tumorerkrankungen
ATE473728T1 (de) Verwendung von fluoreszierenden perlylenverbindungen zur behandlung menschlicher haare
ATE389651T1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
TW200722090A (en) Compounds useful for inhibiting chk1
DE60228073D1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
NO20052153L (no) Piperazin- og piperidinderivater for behandling av nevrologiske sykdommer.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1218494

Country of ref document: EP